文献速递临床微生物分子诊断

细菌转录谱分析作为基因型与表型联合药敏试验的临床先导研究

Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test.
PubMed 文献 · J Clin Microbiol · 2024-10-21

该研究在42份阳性血培养(26份大肠埃希菌、15份肺炎克雷伯菌、1份两者兼有)上首次临床验证GoPhAST-R检测,该法将转录响应谱分析与关键耐药基因转录本检测结合,同时提供表型和基因型数据。GoPhAST-R与标准药敏试验总体一致率为95%,β-内酰胺类最高(98%),氟喹诺酮类最低(88%)。研究证明转录响应谱分析用于快速耐药判定的临床可行性。

要点

  • GoPhAST-R在阳性血培养上直接检测,与标准药敏总体一致率95%。
  • β-内酰胺类一致率最高(98%),氟喹诺酮类最低(88%)。
  • 可检出流行耐药基因如blaCTX-M-15和blaKPC。

核心结论

  • GoPhAST-R在阳性血培养中与标准药敏试验总体一致率达95%,证明转录响应谱分析用于快速耐药判定的临床可行性。

研究设计与样本

  • 首次临床先导研究,在42份阳性血培养(26份大肠埃希菌、15份肺炎克雷伯菌、1份两者兼有)上验证GoPhAST-R检测。
  • 每份阳性血培养等分试样暴露于九种不同抗生素,裂解后在NanoString平台进行快速转录谱分析,结果用内部药敏分类算法分析。

主要发现

  • GoPhAST-R与标准药敏试验方法总体一致率为95%。
  • β-内酰胺类一致率最高(98%),氟喹诺酮类最低(88%)。
  • 在菌群中检出流行耐药基因,包括超广谱β-内酰胺酶blaCTX-M-15和碳青霉烯酶blaKPC。

关键数值与推荐

  • 总体一致率95%,β-内酰胺类98%,氟喹诺酮类88%。
  • 检测了九种不同抗生素。

临床怎么用

  • GoPhAST-R可在阳性血培养上直接进行,整合转录响应谱与耐药基因转录本检测,同时提供表型和基因型数据。
  • 该法有望用于临床快速、全面的抗生素敏感性检测,但需更大规模、更多样化细菌群体的进一步验证。

局限性

  • 样本量有限(42份阳性血培养),需更大规模、更多样化细菌群体进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). Genotypic and Phenotypic AST through RNA detection (GoPhAST-R) is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with the detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli, 15 growing Klebsiella pneumoniae, and 1 with both. An aliquot of each positive blood culture was exposed to nine different antibiotics, lysed, and underwent rapid transcriptional profiling on the NanoString platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase blaCTX-M-15 and the carbapenemase blaKPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.IMPORTANCEExposure to antibiotics causes differential transcriptional signatures in susceptible vs resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of Escherichia coli and Klebsiella pneumoniae in clinically positive blood cultures.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Young EL, Roach DJ, Martinsen MA, et al. Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test. J Clin Microbiol. 2024. PMID: 39431823. doi:10.1128/jcm.00997-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。